ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO1095

Safety and Efficacy of Nirmatrelvir/Ritonavir in Patients with Moderate-Severe CKD with COVID-19: A Real-World Data Study

Session Information

  • COVID-19 - I
    November 02, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Ashruf, Omer S., Northeast Ohio Medical University, Rootstown, Ohio, United States
  • Orozco, Zara C., Northeast Ohio Medical University, Rootstown, Ohio, United States
  • Haq, Imad U., Northeast Ohio Medical University, Rootstown, Ohio, United States
  • Ashruf, Zaid, Northeast Ohio Medical University, Rootstown, Ohio, United States
  • Raina, Rupesh, Cleveland Clinic Akron General, Akron, Ohio, United States
Background

Chronic kidney disease (CKD) is a mortality risk factor for COVID-19, predisposing patients to poor clinical outcomes. Nirmatrelvir/ritonavir (Nm/r) is currently the most effective oral antiviral agent for COVID-19, with 89% reduction in hospitalization and mortality. The U.S. Food and Drug Administration advised against Nm/r in severe CKD patients due to lack of study. In this propensity-matched retrospective study, we assess side effects, efficacy, and severity of clinical outcomes in Nm/r-treated moderate-severe CKD patients with COVID-19.

Methods

Patient data was accessed from TriNetX, a platform that aggregates health record data of over 123 million patients. The experimental group consisted of Stage 3-5 CKD patients, with 2 separate eGFR measurements of <60 mL/min/1.73m2, prescribed Nm/r after COVID-19 infection. The control cohort was any non-CKD patient with COVID-19 prescribed Nm/r. Cohorts were 1:1 propensity matched for age, sex, race, and comorbidities: diabetes mellitus, hypertension, ischemic heart disease, heart failure, cerebrovascular disease, respiratory disease, smoking, and alcohol use. Outcomes assessed were COVID-19 rebound within 5-14 days, side effects within 5-35 days, and clinical outcomes (hospitalization, emergency department (ED) visit, intensive care unit (ICU) admit, and mortality) within 35 days. Odds ratio (OR) and hazard ratio (HR) with 95% confidence intervals (95%Cl) and Kaplan-Meier analysis were calculated.

Results

After matching, 2,491 patients were included in the analysis. Moderate-severe CKD patients were at greater risk of developing nausea/vomiting (OR 4.32, 95%CI 2.35-7.93), diarrhea (OR 2.78, 95%CI 1.64-4.72), and fatigue (OR 1.78, 95%CI 1.23-2.55). These side effects were associated with lower survival probability within 35 days, by 2.1%, 1.6%, and 1.5%, respectively. CKD patients were also at greater risk of COVID-19 rebound (OR 1.33, 95%CI 1.08-1.65), hospitalization (HR 5.75, 95%CI 4.06-8.15), and ED visit (HR 1.68 95%CI 1.29-2.17).

Conclusion

Our findings show that moderate-severe CKD patients fare greater risk of side effects, COVID-19 rebound, and severe outcomes compared to non-CKD high-risk groups even after Nm/r. Providers should counsel patients and monitor the side effect profile and risk of COVID-19 rebound in Nm/r treated CKD patients.

Funding

  • Other NIH Support